Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Lawrence Rubinstein

Statistician

National Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Shivaani Kummar

Oregon Health & Science University

UNITED STATES

View details

Marjorie Zauderer

Section Chief, Hematology & Medical Oncology

New York Medical College

UNITED STATES

View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES

View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES

View details

Elad Sharon

Associate Professor

Harvard University

UNITED STATES

View details

Fengmin Zhao

Biostatistician

Dana-Farber Cancer Institute

UNITED STATES

View details

Karen Reckamp

Cedars-Sinai Medical Center

UNITED STATES

View details

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES

View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES

View details

Kevin Kalinsky

Emory University

UNITED STATES

View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lawrence Rubinstein

Research Interests

Explore related searches

Articles (16)

ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Phase II Study of Vismodegib in Patients With SMO- or PTCH1 -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Collaborators (12)

Shivaani Kummar

Marjorie Zauderer

Lisa McShane

Vivek Subbiah

Elad Sharon

Fengmin Zhao

Karen Reckamp

Sarina Piha-Paul

Robert Gray

Nicholas Mitsiades

Kevin Kalinsky

Mohamed Gouda

Make your next move.